Galangin and TRAIL cooperate to suppress A549 lung cancer proliferation via apoptosis and p38 MAPK activation  by Zhang, Wenjing et al.
Chinese Pharmaceutical AssociationInstitute of Materia Medica, Chinese Academy of Medical Sciences
Acta Pharmaceutica Sinica B
Acta Pharmaceutica Sinica B 2012;2(6):569–5742211-3835 & 2012 In
hosting by Elsevier B
http://dx.doi.org/10.1
nCorrespondings au
E-mail addresses
Peer review under rwww.elsevier.com/locate/apsb
www.sciencedirect.comORIGINAL ARTICLE
Galangin and TRAIL cooperate to suppress A549 lung cancer
proliferation via apoptosis and p38 MAPK activationWenjing Zhanga, Qilai Huangb,n, Zichun Huaa,b,c,naThe State Key Laboratory of Quality Research in Chinese Medicine, Faculty of Chinese Medicine, Macau University of Science and
Technology and Macau Institute for Applied Research in Medicine, Macau, China
bChangzhou High-Tech Research Institute of Nanjing University, Changzhou 213164, China
cThe State Key Laboratory of Pharmaceutical Biotechnology, Nanjing University, Nanjing 210093, China
Received 21 June 2012; revised 28 August 2012; accepted 8 October 2012KEY WORDS
Galangin;
TRAIL;
A549 cell line;
Cytotoxicity;
Apoptosis;
P38 MAPKstitute of Materia M
.V. All rights rese
016/j.apsb.2012.10
thors. Tel.:þ86 25 8
: biocentury@gma
esponsibility of InsAbstract Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising
antitumor therapy against lung cancer which is currently undergoing a phase III clinical trial in
China. Unfortunately some cancer patients in the clinical trial displayed resistance to TRAIL
treatment. In investigating ways to overcome this resistance, we evaluated the inhibitory effect of
galangin on TRAIL resistant A549 human lung adenocarcinoma cells. Here we report that, in
comparison with the single agents, the combination of galangin and TRAIL markedly suppressed
proliferation of A549 cells and induced apoptosis as shown by DAPI and JC-1 staining. The
combination of galangin and TRAIL induced PARP cleavage, activation of caspase-8 and p38
MAPK (mitogen-activated protein kinases). These ﬁndings indicate that the combination of
galangin and TRAIL may constitute a promising strategy for the treatment of lung cancer.
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Lung cancer is the world’s leading cause of cancer deaths and
a disease for which conventional therapy has only limited
success1. Lung carcinomas are classiﬁed into non-small cell
lung carcinomas (NSCLCs) and small cell lung carcinomas
(SCLCs), the former being epithelial tumors that represent
80% of all lung carcinomas. Tumor necrosis factor-related
apoptosis inducing ligand (TRAIL), a member of the tumor
necrosis factor family of cytokines, is a promising antitumor
agent which selectively induces cell death in most tumor cells
while leaving most normal cells unaffected2. However, some
tumor cells are resistant to TRAIL, including some NSCLC
cell lines such as A5493–5 and some patients displayed
resistance to TRAIL treatment during a phase II clinical trial.
Clearly, it is important to overcome this resistance to improve
TRAIL efﬁcacy in treating lung cancer.
Galangin, a major ﬂavonoid in propolis, comprises approxi-
mately 10% of the ethanolic extract of Alpinia ofﬁcinarum6
which is widely used in Asia as a herbal medicine7,8. Galangin
inhibits the growth of human mammary tumor cells by
hindering the transition of cells from the G0/G1 to the S
phase9. It also induces apoptosis of hepatocellular carcinoma
cells via the mitochondrial pathway10. In addition, a recent
study found that an ethanolic extract of propolis signiﬁcantly
sensitized prostate cancer cells to TRAIL-inducing apopto-
sis11. However, the detailed cellular and molecular mechanism
of this process and the speciﬁc role of galangin remain
unknown. More importantly, whether the ability of galangin
to sensitize cancer cells to TRAIL treatment also applies to
lung cancer cells remains unclear.
In this study, we investigated the effect and molecular
mechanism of single and combined treatment with galangin
and TRAIL on A549 lung cancer cells.2. Materials and methods
2.1. Chemicals and reagents
Galangin and TRAIL were obtained from the Guangzhou
Institute for Drug Control (Guangzhou, China) and the
State Key Laboratory of Pharmaceutical Biotechnology,
Nanjing University, respectively. A stock solution of galangin
(100 mM) in DMSO was prepared and stored at 20 1C when
not in use. For in vitro use, the galangin stock solution was diluted
in F-12k medium and TRAIL was dissolved in phosphate-
buffered saline (PBS). The solutions were used immediately and
any excess discarded. Anti rabbit phosphorylation-p38 MAPK,
p38 MAPK, caspase-8 and PARP were purchased from Cell
Signaling Technology (Danvers, MA, USA). Anti-mouse
GAPDH was obtained from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Goat anti-mouse IgG IRDye 800 CW and
donkey-anti-rabbit IgG IRDye 800 CW were purchased from
LI-COR Biosciences (Lincoln, NE, USA).
2.2. Cell culture
The A549 human non-small cell lung cancer cell line was
obtained from the State Key Laboratory of Pharmaceutical
Biotechnology, Nanjing University, and cultured in F-12k
medium supplemented with a mixture of 10% fetal bovineserum (FBS), 1% penicillin (100 units/mL) and streptomycin
(100 mg/mL) (Gibco, USA) at 37 1C in a humidiﬁed atmo-
sphere containing 5% CO2.
2.3. Cell viability assay
Cell viability was measured using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Brieﬂy, cul-
tured A549 cells were harvested, counted and seeded (3,000
cells) into a 96-well microtiter plate. The cells were treated with
TRAIL (80 ng/mL) or varying concentrations of galangin (20,
40, 60 and 80 mM)4,12, or a combination of 60 mM galangin and
80 ng/mL TRAIL for 24 h. After incubation, the cells were
washed twice with PBS and then incubated with 15 mL MTT
(5 mg/mL in PBS) dissolved in 150 mL F-12k for another 4 h at
37 1C. Finally, the medium was aspirated from each well and
150 mL DMSO added to dissolve formazan crystals. The plate
was analyzed on a microtiter plate reader (Molecular Devices;
Sunnyvale, CA, USA) at a test wavelength of 570 nm and a
reference wavelength of 630 nm. Cell viability (%) was calculated
as (absorbance of test sample/absorbance of control) 100%.
2.4. Cell morphology
A549 cells were seeded on a 6-well plate at a density of 5 105
cells/well and cultured overnight. The cells were treated with either
80 ng/mL TRAIL, 60 mM galangin or both for 24 h at 37 1C in a
humidiﬁed atmosphere containing 5% CO2. The cells were then
ﬁxed in 3.7% paraformaldehyde and washed with PBS. Cells were
photographed using an inverted phase contrast microscope (IX71,
Olympus, Tokyo, Japan) at 20 magniﬁcation.
2.5. DAPI staining
The rate of apoptosis was quantiﬁed by DAPI staining. A549
cells were treated as in Section 2.4 and then treated with DAPI
staining solution (Beyotime Institute of Biotechnology, Nanj-
ing, China) for 3–5 min. After staining, cells were washed with
PBST and examined using a ﬂuorescence microscope (IX71,
Olympus, Tokyo, Japan) at 40 magniﬁcation.
2.6. JC-1 staining
The mitochondrial membrane potential was assessed using the
ﬂuorescent probe JC-1 dye (Beyotime Institute of Biotechnol-
ogy, Nanjing, China). Brieﬂy, A549 cells were treated as in
Section 2.4 and then incubated with JC-1 working solution for
20 min at 37 1C in the dark. Cells were washed with cold JC-1
staining buffer, placed on ice and observed immediately by
ﬂuorescence microscopy (IX71, Olympus, Tokyo, Japan) at
20 magniﬁcation using FITC and TRITC channels.
2.7. Western blot analysis
A549 cells were harvested by gentle scraping under lysis buffer
[50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1% Triton-X 100,
0.5% sodium deoxycholate, 0.1% SDS, 5 mM EDTA, 10 mM
NaF, 1 mM sodium vanadate (Na3VO4), 10% glycerol and
1 mM EGTA]. Cells were incubated on ice for 30 min,
centrifuged at 12,000 g for 30 min at 4 1C and protein
concentration determined using the Bradford assay. For
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electrophoresis on 10% SDS–PAGE gels and transferred to
nitrocellulose membranes. The proteins were probed with the
antibodies listed in Section 2.1. Signal detection after second-
ary antibody incubation was done using the Odyssey infrared
system (Lincoln, NE, USA).
2.8. Statistical analysis
Data are presented as mean7standard error of the mean
(SEM). Differences between groups were assessed by one-way
ANOVA and signiﬁcance of difference between particular
treatment groups was analyzed using Dunnett’s multiple
comparison test or the Bonferroni test (GraphPad Prism 5.0
software, La Jolla, CA). Differences for Po0.05 were con-
sidered statistically signiﬁcant.Figure 1 Effect of galangin and TRAIL on A549 cell viability
as determined in the MTT assay. (A) Cells treated with galangin
(20, 40, 60 and 80 mM) for 24 h. Po0.01 vs. untreated group;
Po0.001 vs. untreated group. (B) Cells treated with galangin
60 mM and/or TRAIL 80 ng/mL for 24 h. #Po0.05 vs. galangin
60 mM alone. Data are mean7SEM (n¼3).3. Results
3.1. Effect of galangin and/or TRAIL on cell viability
Using the MTT assay, treatment with 0-80 mM galangin for 24 h
was shown to suppress cell viability in a dose-dependent manner
(Fig. 1A). Cell viability at 60 and 80 mM galangin was reduced to
73.6% and 49.6% of control and the differences were statistically
signiﬁcant (Po0.01). Treatment with 80 ng/mL TRAIL did not
affect cell proliferation of A549 cells compared with control
(Fig. 1B) but the combination of galangin and TRAIL decreased
cell viability by 20.6% compared to 60 mM galangin alone
(Po0.05). In subsequent experiments, 60 mM galangin and/or
80 ng/mL TRAIL were used to assess effects on A549 cells.
3.2. Effect of galangin and/or TRAIL on cell morphology
Control A549 cells and those treated with TRAIL alone showed
no morphological changes demonstrating the resistance of A549
cells to TRAIL-induced apoptosis (Fig. 2). The cells were healthy
and fusiform with clear outlines in both groups. Cells treated
with 60 mM galangin alone were enlarged whereas those treated
with the combination showed cell shrinkage and detachment. In
both case, the number of A549 cells decreased (Fig. 2).
3.3. DAPI staining
DAPI staining indicated that cells treated with the combina-
tion of 60 mM galangin and 80 ng/mL TRAIL displayed cell
shrinkage and dot-shaped nuclear fragments indicative of
markedly increased apoptosis (Fig. 3A). In fact, the rate of
apoptosis increased signiﬁcantly in the combination group
(Po0.001) (Fig. 3B). Treatment with galangin alone was
found to decrease the number of cell nuclei.
3.4. JC-1 staining
JC-1 aggregates in normal mitochondria and presents red
ﬂuorescence indicative of normal Dcm. This was the case in
the control and TRAIL treatment groups (Fig. 4). Exposure to
60 mM galangin and/or 80 ng/mL TRAIL resulted in dissipa-
tion of Dcm as shown by increased green ﬂuorescence and, in
the combination group, decreased red ﬂuorescence.3.5. Western blotting
Western blot analysis was performed to assess the effects of
treatment of A549 cells on PARP and caspase-8. As
demonstrated in Fig. 5, TRAIL alone slightly increased
the cleavage of caspase-8 and induced the cleavage of PARP
to cle-PARP at 89 kDa (Po0.01). Galangin alone decreased
procaspase-8 and PARP but there was no cleavage form
produced. The combination of galangin and TRAIL highly
induced the activation of caspase-8 and cleavage of PARP
(Po0.001).
A number of previous studies have assessed expression of
phosphorylated and total proteins of MAPK pathways and
demonstrated that activation of MAPK signaling pathways is
often implicated in apoptosis by chemotherapeutic agents. Our
results show that, among the MAPK pathways, TRAIL,
galangin, and their combination only activate p38 MAPK.
Moreover, p38 MAPK was dramatically phosphorylated by
treatment with the combination of galangin and TRAIL
compared with galangin alone (Po0.05). All treatments had
no effect on total proteins levels. Our results indicate that both
TRAIL and galangin induce apoptosis of A549 cells through
modulating the p38 MAPK pathway.4. Discussion
The ﬂavonoids, which are primarily benzo-g-pyrone (phenyl-
chromone) derivatives, comprise a very large class of naturally
Figure 3 DAPI staining of A549 cells. (A) Representative
photomicrographs (40 magniﬁcation; scale bar 20 mm) of cells
after exposure to galangin 60 mM and/or TRAIL 80 ng/mL for
24 h. (B) Apoptosis rate determined by counting the number of
apoptotic cells. Po0.001 vs. control group. Data are
mean7SEM for duplicate wells repeated three times (ﬁve ﬁelds
per well).
Figure 2 Effect of galangin and TRAIL on A549 cell morphology. A549 cells were treated with galangin 60 mM and/or TRAIL 80 ng/mL
for 24 h. Cells were photographed by an inverted microscope at 20 magniﬁcation; scale bar 50 mm.
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Accumulating evidence indicates that ﬂavonoids not only
inhibit the growth of tumor cells but also act synergistically
with other chemotherapeutic agents to promote tumor cell
apoptosis14,15. TRAIL is a promising anticancer agent usedalone or in combination with other agents16. The ﬂavone
apigenin was shown to restore TRAIL sensitivity to TRAIL
resistant Hela cells15. Kaempferol and quercetin in combina-
tion with TRAIL acted synergistically to induce apoptosis in
prostate and colon cancer cells17,18. The study by Szliszka
et al.11 showed that a combination of propolis and TRAIL
induced apoptosis in prostate cancer cells. The current study
has shown that galangin, an active ﬂanonoid in propolis, in
combination with TRAIL suppresses proliferation and
increases apoptosis in A549 lung cancer cells.
In terms of the mechanism of action, JC-1 staining revealed
that disruption of Dcm is produced not only by galangin alone
but also by the combination of galangin and TRAIL. These
results are consistent with previously reported data showing
that galangin mediates apoptosis through a mitochondrial
pathway10,19. As for TRAIL, activation of TRAIL receptors
recruits and activates an adapter FADD which, in turn,
recruits and activates caspase-8. Once caspase-8 is activated,
it can lead to apoptosis either by caspase-3 and -7, or by Bid,
which initiates the mitochondrial apoptotic pathway20. In the
current study, cleavage of procaspase-8 was observed to result
from treatment with the combination but not galangin alone.
Activation of caspase-8 may lead to the processing of its
substrate Bid which then translocates to the mitochondria and
disrupts Dcm21. It is showed that PARP, another marker of
apoptosis22, is cleaved signiﬁcantly as a result of the combina-
tion treatment.
As reported elsewhere, MAPKs are also activated during
TRAIL-induced apoptosis, and their activation is caspase-8-
dependent23. In the present study, It is showed that galangin
also modulates p38 MAPK and that the combination results
in even greater phosphorylation of p38 MAPK. However,
changes in the phosphorylation of JNKs and ERKs were not
detected. It has been reported that ROS and p38 MAPK are
both involved in TRAIL-induced apoptosis24. Ohtsuka et al.25
also showed that adriamycin and cisplatin enhance TRAIL
receptor agonistic antibody-mediated apoptosis by activation
of p38 MAPK and JNK. Another ﬂavonoid, genistein,
contributed to TRAIL-induced apoptosis in Hep3B cells by
triggering the inhibition of p38-b MAPK activation26. It
should be noted that the activation of p38 MAPK is not only
dependent on stimulus but also on cell types. On the basis of
our results, we speculate that activation of p38 MAPK
participates in galangin- or galangin-and-TRAIL-induced
apoptosis in A549 cells.
Figure 4 Effect of galangin and/or TRAIL on the mitochondrial membrane potential (Dcm) of A549 cells treated with galangin 60 mM
and/or TRAIL 80 ng/mL for 24 h. Cells were stained with JC-1 dye and the ﬂuorescence shift was observed according to the
manufacturer’s instructions (20 magniﬁcation; scale bar 50 mm). Galangin 60 mM induces collapse in Dcm and the combination induces
an evident drop in Dcm. Experiments were carried out in triplicate.
Figure 5 Results of Western blotting for caspase-8 and PARP in A549 cells. (A) Cells treated with galangin 60 mM and/or TRAIL 80 ng/
mL for 24 h. In addition, MAPKs were evaluated. For total proteins and phosphorylation forms of MAPK, the membrane was ﬁrst
incubated with antibody against phosphor-MAPKs and then the same blot was stripped and reprobed with total MAPK antibody (data
for JNK and ERK are not shown). GAPDH was used as internal control. The results shown are from one of two duplicate experiments
showing a similar pattern. (B) Quantiﬁcation of results in A. Procaspase-8, PARP and total p38 were used as internal standards in
quantiﬁcation of cle-caspase-8, cle-PARP and phosphorylation of p38, respectively. Po0.01 and Po0.001 for treated vs. untreated
cells. #Po0.05 for cells treated with galangin alone vs. the combination.
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Our results indicate that the combination of galangin and
TRAIL is a promising strategy to treat A549 lung cancer.
However, further studies of the combination should be carried
out with a p38 MAPK inhibitor to illuminate the role of p38
MAPK in galangin– and TRAIL-induced effects.
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